Podcasts about Mariposa

En tiempos donde la inteligencia artificial ocupa los titulares, este episodio es una ofrenda a otra forma de saber: la inteligencia ancestral y animal, la que habita en el cuerpo, en el silencio, en la tierra. Junto a Caliche Montoya -fotógrafo, viajero, fundador de Colombia Inspira, compañero de aventuras y gran amigo- conversamos sobre la intuición, la escucha profunda y el arte de ir al ritmo de la mariposa: lento, sensible y lleno de sentido. Hablamos también del viaje como maestro, de lo que se aprende en el desplazamiento, cuando lo desconocido nos obliga a afinar el oído, mover el centro, abrir el cuerpo. Porque a veces es lejos de casa donde comenzamos a entender lo esencial.

Buenos días, soy Yoani Sánchez y en el "cafecito informativo" de este lunes 28 de julio de 2025 tocaré estos temas: - Un reporte oficial con precios "maquillados" desata la indignación - Altos consumidores de combustible, los todoterrenos rusos ensamblados en Cuba - La violencia machista se cobra otra víctima - Exposición ‘La estrategia del Bambú' Gracias por compartir este "cafecito informativo" y te espero para el programa de mañana. Puedes conocer más detalles de estas noticias en el diario https://www.14ymedio.com Los enlaces de hoy, para abrirlos desde la Isla se debe usar un proxy o un VPN para evadir la censura: El secreto bien guardado del éxito de la empresa estatal La Cuba en Ciego de Ávila https://www.14ymedio.com/economia/secreto-guardado-exito-empresa-estatal_1_1116348.html Maltratada durante años, Kenia muere al ser arrojada por su pareja desde la azotea de su vivienda https://www.14ymedio.com/cuba/maltratada-durante-anos-kenia-muere_1_1116373.html Altos consumidores de combustible, los todoterrenos rusos que rodarán por las calles cubanas https://www.14ymedio.com/cuba/altos-consumidores-combustible-todoterrenos-rusos_1_1116335.html Regresa la Mariposa: promesas, ruinas y nostalgia en el parque Lenin de La Habana https://www.14ymedio.com/cuba/regresa-mariposa-promesas-ruinas-nostalgia_1_1116322.html "Sin 'Mazzantini' no hay país" https://www.14ymedio.com/cultura/mazzantini-no-hay-pais_1_1116315.html Rusia propone crear un ‘Silicon Valley' en la Isla de los apagones https://www.14ymedio.com/cuba/rusia-propone-crear-silicon-valley_1_1116310.html El rapero Nando OBDC se mantiene en huelga de hambre y está incomunicado https://www.14ymedio.com/cuba/rapero-nando-obdc-mantiene-huelga_1_1116356.html Una madre desesperada recorre La Habana en busca de su hija desaparecida hace cuatro meses https://www.14ymedio.com/cuba/madre-desesperada-recorre-habana-busca_1_1116346.html Una abuela cubana recibe una orden de deportación tras 30 años en EE UU https://www.14ymedio.com/migracion/abuela-cubana-recibe-orden-deportacion_1_1116353.html ​​La estrategia del Bambú, exposición de Felipe Dulzaides https://www.14ymedio.com/cartelera/estrategia-bambu-exposicion-felipe-dulzaides_1_1116214.html

Aseguran bodega con combustible robado en Tres Marías, MorelosMás de 200 jardines y huertos polinizadores para la mariposa monarca Netanyahu condena decisión de Macron de reconocer al Estado palestinoMás información en nuestro Podcast

Assemblyman David Tangipa joins Darcy and Darcy for a great conversation that covers a wide range of California issues and topics! For those that don't know him yet, David is the youngest person serving in the California legislature. He was elected to the California State Assembly in 2024 and represents District 8, which includes Calaveras, Fresno, Inyo, Madera, Mariposa, Mono, and Tuolumne counties.  Darcy & Darcy discuss with David his perspective on the business of California's legislature, his first six months in office, some great ideas he has about putting existing infrastructure to work doing double duty, the impact the Groundwater Sustainability Act has had on his constituents, and most importantly, lessons learned.One thing is clear: David is an upcoming California policy leader. The ECPAC is looking forward to hosting a fundraiser for David on July 31st at noon at M & M's Italian Restaurant in Los Banos. If you would like to support David or join us for lunch, please contact Terra at (559) 281-9088 or email her at tbrusseau@centralvalleygroup.com. All are welcome to attend.To learn more about Assemblyman Tangipa and District 8 visit www.ad08.asmrc.org/.Send us a textWe Grow California Podcast is paid for by the Exchange Contractors Federal PAC and Exchange Contractors State PAC and is not authorized by any candidate or candidate committee.

 Em agosto de 2021, a família Gerrish, composta por John, Ellen, Miju e Oski foram fazer uma trilha na Floresta Nacional de Sierra, no Condado de Mariposa. Depois que eles não voltaram para casa, seus amigos acionaram as autoridades. O que aconteceu com a família Gerrish? #510

Este es un ncuentro muy especial, pensado para abrazar a quienes transitan el dolor más profundo: la pérdida gestacional y neonatal.

Episode Description:In this uplifting episode, “The Butterfly Who Wanted to Fly”, we meet Lila, a colorful little butterfly with big wings—and an even bigger fear of flying. With the help of her friend Nico the hummingbird, Lila learns that courage isn't about being unafraid, but about trusting yourself enough to try. This gentle story is all about bravery, growth, and taking that first leap.Want the full transcript, vocabulary list, and printable story bundle? Join our monthly membership to support the podcast on Patreon at patreon.com/spanishstoriesforkids.And if you have a story you'd like us to read, email us at spanishstoriespodcast@gmail.com—we'd love to hear it!En este episodio inspirador, “La Mariposa Que Quería Volar”, conocemos a Lila, una pequeña mariposa llena de color, con alas grandes… y un miedo aún más grande a volar. Con la ayuda de su amigo Nico, un colibrí, Lila aprende que el valor no significa no tener miedo, sino confiar lo suficiente en uno mismo para intentarlo. Esta historia suave nos habla de la valentía, el crecimiento y ese primer gran salto.¿Quieres la transcripción completa, la lista de vocabulario y un paquete imprimible del cuento? Únete a nuestra membresía mensual para apoyar el podcast en Patreon: patreon.com/spanishstoriesforkids.¿Tienes una historia que te gustaría que leamos? Escríbenos a spanishstoriespodcast@gmail.com—¡nos encantaría recibirla!

Dr. Joshua Reuss joints that podcast to discuss the latest changes to the living guideline on stage IV NSCLC with driver alterations. He discusses the new evidence for NSCLC with EGFR mutations and NRG1 fusions and how this impacts the latest recommendations from the panel. He shares ongoing research that the panel will review in the future for further updates to this living guideline, and puts the updated recommendations into context for clinicians treating patients with stage IV NSCLC. Read the full living guideline update “Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1” at www.asco.org/thoracic-cancer-guidelines TRANSCRIPT This guideline, clinical tools, and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-01061 Brittany Harvey: Hello and welcome to the ASCO Guidelines Podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Joshua Reuss from Georgetown University, co-chair on "Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1." It's great to have you here today, Dr. Reuss. Dr. Joshua Reuss: Thank you. Happy to be here. Brittany Harvey: And then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Reuss, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So to dive into what we're here today to talk about, Dr. Reuss, this living clinical practice guideline for systemic therapy for patients with stage IV non–small cell lung cancer with driver alterations is updated on an ongoing basis. So what prompted this latest update to the recommendations? Dr. Joshua Reuss: Yes, thank you. It's very important that we have living guidelines that are continuously updated. We obviously don't live in a static environment where things are non-changing, and we really need to apply the most up-to-date and current evidence to treat our patients with the most effective strategies, the most groundbreaking strategies. And so to have guidelines that can be disseminated, particularly these ASCO guidelines, to treating providers is incredibly important. So, with any of these updates, we review ongoing studies, published work, for the quality of evidence to see if it's something that warrants making adjustments to our guidelines or at least incorporating the information so that providers can review it and incorporate this into their own personal decision-making. So in this particular update, we reviewed evidence particularly pertaining to EGFR-mutated non–small cell lung cancer and non–small cell lung cancer harboring an NRG1 fusion. Brittany Harvey: Yes, certainly there's a lot of new evidence in the advanced non–small cell lung cancer field, and so we appreciate the panel's continuous review of this evidence. So then you just mentioned two separate areas where the panel reviewed new evidence. So starting with that first one, what updated evidence did the panel review on first-line treatment options for patients with EGFR alterations, and how did this impact the recommendations? Dr. Joshua Reuss: Yes, so advanced EGFR-mutated non–small cell lung cancer, at least with classical activating alterations - that is our exon 19 deletions and our exon 21 L858R mutations - is something that's really evolved rapidly in the last few years. You know, for many years, we basically, for the frontline treatment setting, were saying, "Okay, we have a targeted therapy, osimertinib. We're going to give that, and we're going to see what effect we can get out of that," with, you know, a median time of duration of treatment response averaging around 18 months, knowing that there are some that that's a lot longer and some that are a lot shorter. But recently, we've seen a lot of data emerging on combination strategies. The guideline has already been updated to incorporate two of these combinations: osimertinib with chemotherapy based off of the FLAURA2 trial, and then the combination of amivantamab with lazertinib based off of the MARIPOSA trial. And that was data on progression-free survival that was published and led to those particular recommendations. Now, more recently, we've seen data come out in smaller, randomized studies for other combinations. And more recently, we reviewed the RAMOSE study. So this was a phase II, open-label, randomized trial for patients with tyrosine kinase inhibitor–naive and really, treatment-naive advanced EGFR-mutated non–small cell lung cancer harboring one of these two classical EGFR alterations, randomized to either osimertinib alone or osimertinib with the combination of ramucirumab, which is an anti-VEGF agent. There's been a lot of data, preclinical and clinical, for the role of VEGF blockade, particularly in EGFR-mutated non–small cell lung cancer, so exploring the combination of this for synergy in the frontline setting really made a lot of sense. So again, this was a phase II trial that randomized patients prospectively to one of these two regimens. The population here is really what we typically see with EGFR-mutated non–small cell lung cancer, predominantly a younger population - median age on this study was 65 - predominantly female - 71% female - and predominantly nonsmokers. Now, what this study showed was that at a median follow-up of 16.6 months, the progression-free survival favored the combination arm with a median progression-free survival of 24.8 months with the combination of osimertinib plus ramucirumab versus 15.6 months for osimertinib alone, for a hazard ratio of benefit of 0.55. The landmark one- and two-year endpoints for progression-free survival also favored the combination arm, and response rates were relatively comparable between groups, with overall adverse events being more frequent in the combination group, specifically high blood pressure, proteinuria, and epistaxis, which are our common adverse events related to VEGF-blocking agents. So, it's good to see data in this space. Now, of note, though, this was a phase II study, so not a phase III level of evidence. In addition, when looking at the population, this was a randomized, multicenter study, but it was a US-only population. There was also some imbalance in the number of visits between arms, so the combination arm was seen more frequently than the arm that got osimertinib alone. Now, the imaging assessments were no different, but obviously this could lead to potential confounding, at least in timing of awareness of potential side effects and and things being brought to the attention of investigators. So very promising data here, but because, you know, of this being a phase II study, this actually led to no changes in the guideline at this time. Brittany Harvey: Understood. Yes, as you mentioned prior, it's important to understand the full body of evidence and to review the trials even when it doesn't impact the recommendations. Dr. Joshua Reuss: And I will say that, you know, there is an ongoing phase III study looking at a very similar combination. It's the phase III ECOG-ACRIN trial of the combination of osimertinib plus bevacizumab versus osimertinib alone in this specific population. So, you know, I think we will see phase III–level data for a combination of VEGF with osimertinib, but again, promising phase II data that did not lead to a change in the recommendation at this time. Brittany Harvey: Absolutely. We'll look forward to that ongoing trial to learn more about combination in this patient population. So then moving to that second patient population that you mentioned earlier where the panel reviewed evidence, what is the updated evidence and recommendation for patients with NRG1 fusions? Dr. Joshua Reuss: Yeah, so this was an exciting update that we made more recently with this unique iteration of the living guidelines. So, NRG1 fusions, this is perhaps a newer kid on the block in terms of driver alterations that has been known to be identified in non–small cell lung cancer among other solid tumors. It is very rare, occurring in less than 1% of solid tumors, but something that we know is a unique oncogenic pathway that can lead to oncogenesis and cancer development, including in non–small cell lung cancer. So up until now, unfortunately, there have not been targeted therapies that target this unique alteration. It's somewhat different than other driver alterations where there's a top-level signaling change in a protein. This is more of a ligand alteration that then alters, that then enables activation of more classical pathways, but again, through upregulation of a unique ligand. So a slightly different pathway but something that we know should be able to be targeted to promote patient survival for those with NRG1 fusions. So the therapy here is a therapy called zenocutuzumab. It's an IgG1 bispecific antibody against HER2 and HER3. So it prevents the downstream dimerization and signaling that occurs as a result of this NRG1 fusion and upregulation of the NRG1 signal. This was, as you can imagine with a rare alteration, a large phase II registrational study that examined this in advanced solid tumors containing the NRG1 fusion. This is the NRG1 registrational trial. And this study enrolled patients with advanced solid tumors who had progressed on prior therapy. Patients were treated with zenocutuzumab 750 milligrams IV every two weeks. Among 158 response-evaluable solid tumor patients, the response rate was 30%, median duration of response of 11.1 months, and a median progression-free survival of 6.8 months. Now, in those with non–small cell lung cancer, that made up 93 response-evaluable patients, very similar outcomes there: a response rate of 29%, median duration of response of 12.7 months, and a median progression-free survival of 6.8 months. This therapy did appear to be well tolerated. The most common higher-grade emergent side effects - grade 3 or higher - were anemia occurring in 5% and elevated liver numbers occurring in 3%. So this is a subsequent-line study, so this led to the updated recommendation that clinicians may offer zenocutuzumab in the subsequent-line setting for patients with advanced non–small cell lung cancer who harbor NRG1 fusions. So I think this does speak toward the incredible importance of next-generation sequencing and molecular testing for patients, particularly to include testing that looks at the RNA. These large fusions can sometimes be very challenging to detect on DNA sequencing platforms alone, so it's important to, if you have a high level of suspicion for an alteration like this, perhaps some of the mucinous adenocarcinomas where it's been challenging to find a driver alteration, and it's someone who is a never-smoker, really would want to include molecular testing that assesses the RNA level and not just the DNA. Brittany Harvey: Absolutely. It's important to have all the biomarkers available so that clinicians are able to use that to inform their decision-making. So then, given these changes in the guideline, what should clinicians know as they implement this latest living guideline update? And how do these changes impact patients? Dr. Joshua Reuss: Yeah, I think talking in reverse order of what we just discussed here, there is a new guideline update for NRG1 fusions. So I think making sure that that's being evaluated, that clinicians are testing for that and really looking for that result that should be incorporated in in most next-generation large sequencing assays to get that result, but it's very important that that is not overlooked now that we do have a therapy that's available in the subsequent-line setting, though it is important to note that patients with NRG1 fusions, at least the limited data that there is suggests that the efficacy to standard chemoimmunotherapy regimens is overall poor. So physicians unfortunately might be facing this question for second-line therapy in patients with NRG1 fusions sooner rather than later. For the former, for EGFR-altered non–small cell lung cancer and how do we incorporate VEGF-containing regimens into these patients? Our guideline top-level update did not change based off of review of this new study, but it's important for clinicians to know what other combinations may exist. You know, there are phase III studies looking at this combination in the frontline setting. And of course, there is data on other bispecific molecules that incorporate VEGF in the subsequent-line setting, particularly a combination that includes the VEGF/PD-1 bispecific antibody ivonescimab that's being studied in the HARMONi-A trial for patients with EGFR-mutated advanced non–small cell lung cancer, for which we hope to get some more definitive data in the coming months. Brittany Harvey: Definitely. And then you've just mentioned a few ongoing trials where we're looking for evidence to inform future updates. But thinking beyond that, into the future, what is the panel examining for future updates to this living guideline? Dr. Joshua Reuss: It's a very exciting time to be in the world of treating advanced non–small cell lung cancer, particularly patients with driver alterations, because there is so much evolving data that's changing our practice in real time, again highlighting the importance of these living guideline updates. I'd say there's many things that we're excited to see. You know, a lot of the combination regimens in EGFR-mutated non–small cell lung cancer for which there are approvals and current recommendations in our guideline, particularly osimertinib plus chemotherapy and amivantamab plus lazertinib - those are the two approved combination strategies in the front line - we are now seeing the emergence of overall survival data for those combinations. So obviously that is something that's going to be very important for the committee to review and incorporate into guideline updates. There are several new therapies coming down the road for other driver populations. We recently saw an approval for taletrectinib for ROS1 fusion–positive non–small cell lung cancer, so it's going to be important that the committee reviews the data and the publications regarding that therapy. And then there are other novel therapies that we're looking to see updated data on. There are multiple antibody-drug conjugates, which take the potent power of a chemotherapy molecule and attempt to make that targeted with an antibody targeting to a unique feature on the cancer cell. And there are several antibody-drug conjugates that are in development at various levels of promise in this space, particularly in EGFR-mutated non–small cell lung cancer, and I anticipate seeing some emerging data for that coming up in the near future as well. So really, lots to be excited in the space and lots for our committee to review to give guidance on so that these patients can really receive the top-level care wherever they are being treated in the country and throughout the world. Brittany Harvey: Yes, we'll await this new data to continue to provide optimal options for patients with stage IV non–small cell lung cancer with driver alterations. So, Dr. Reuss, I want to thank you so much for your work to rapidly and continuously update and review the evidence for this guideline and thank you for your time today. Dr. Joshua Reuss: Thank you so much. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines Podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available on the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

El reto Igare continua, segundo capítulo de este reto que esta llevando a Javier Garcia Reboredo (Xinolugo) a completar las tres grandes citas del ciclismo por etapas. Giro, Tour y Vuelta; Con el Giro ya finiquitado llega el turno del Tour de Francia.Hablamos con Xino para que nos cuente como ha recuperado y sobre todo como afronta esta segunda cita del año que lo llevará a recorrer las etapas mas traslados del Tour de Francia en autosuficiencia, en favor de la asociación Debra Piel de Mariposa.https://igare.ccHaz tu donación al reto -> https://www.migranodearena.org/reto/igareBSO: https://calmaquebranto.bandcamp.com/album/otras-formas-de-arderEmpresas colaboradoras con el reto:@pieldemariposa@ritcheylogic@frasen_wheelworks@geosminacomponents@mountain_group@lezyneofficial@oldmanmountainracks@fmchallenge@silca_velo@ruta_29@novafis_fisioterapia@selo_roupabonita@strava@reneherse

Quarta-feira, 25 de janeiro de 2025.

La m

El Viene y Va podcast regresa después de 6 meses, más honesto, más divertido, más fresco. En el episodio de hoy, Dani cuenta sobre un encuentro que tuvo con alguien de su pasado, y como este momento la llevó a aprender más sobre el efecto mariposa y como se aplica al día a día.www.danigschulz.com | IG: @danigschulz | TikTok: @danigschulz

Artificial Intelligence seems to be everywhere including personal finance. Credit Canada has now launched an AI debt management agent called Mariposa. Natasha Kinnear, the Digital Delivery Manager, joins us to tell us how it works. Find out more about Credit Canada on Facebook, X/Twitter, LinkedIn, Instagram, YouTube, and TikTok. Connect with Natasha on LinkedIn.

Canadians are struggling to make their monthly payments on credit cards and mortgages. Rebecca Oakes, Vice President of Advanced Analytics at Equifax Canada, tells us about their latest findings.  Then,  what do you do about your finances if you lose your job? Aravind Sithamparapillai, an associate at Ironwood Wealth Management Group, tells us how to handle a layoff. And how to play the loyalty points game. Barry Choi, personal finance expert, takes us through the rules and how to win. Plus, we'll speak with Natasha Kinnear, Credit Canada's Digital Delivery Manager, about their Mariposa AI agent that helps with debt management. To find out more about the guests check out: Rebecca Oakes: X/Twitter Credit Canada: Facebook | X/Twitter | LinkedIn | Instagram | YouTube | TikTok Natasha Kinnear: LinkedIn Aravind Sithamparapillai: X/Twitter and LinkedIn Barry Choi: moneywehave.com | Instagram Bruce Sellery is a personal finance expert and best-selling author. As the founder of Moolala and the CEO of Credit Canada, Bruce is on a mission to help you get a better handle on your money so you can live the life you want. High energy & low B.S., this is Moolala: Money Made Simple. Find Bruce Sellery at Moolala.ca | Twitter | Facebook | LinkedIn

Paty explains how shame is an internal message of unworthiness while guilt is linked to specific actions. They explore the roots of these feelings, often tied to past experiences, and offer practical strategies for self-regulation to break cycles of intergenerational trauma. Learn how to foster a healthier self-dialogue and pass down positive behavior patterns to your children.04:29 Understanding Trauma-Informed Care07:53 Exploring Mom Guilt and Shame10:46 Differentiating Guilt and Shame18:04 Addressing Core Beliefs, Self-Compassion, and Grieving24:30 Understanding Trauma and Its Impact28:04 Self-Regulation Techniques32:43 Daily Practices for Self-RegulationPaty ‘Mariposa' Hernandez is a Trauma-Informed Licensed Clinical Social Worker and Reiki Master specializing in education, training, and leading retreats. She helps transform stress and trauma into inner peace using complementary therapies. She's happily married with 3 cats in Miami!Connect with Paty ‘Mariposa' Hernandezwww.mariposasholistic.com Connect with Paige BondInstagram: @paigebondcoachingFacebook: @paigebondcoachingTikTok: @paigebondcoachingWebsite: https://paigebond.comPaige Bond is an open relationship coach who specializes in helping individuals, couples, and intentionally non-monogamous relationships with feeling insecure in their relationships. She is also the founder of ⁠Sweet Love Counseling⁠ providing therapy in CO, FL, SC, and VT. Paige loves educating people about relationships through being the host of ⁠the Stubborn Love podcast, ⁠hosting workshops, and speaking at conferences.Free Jealousy Workbook: ⁠⁠⁠http://www.paigebond.com/calm-the-chaos-jealousy-workbook-download⁠⁠⁠ Free People Pleasing Workbook: ⁠⁠⁠https://www.paigebond.com/people-pleasing-workbook⁠⁠⁠ Attachment Dynamics Workshop:⁠https://www.paigebond.com/attachment-dynamics-workshop-sign-up⁠Disclaimer: This podcast and communication through our email are not meant to serve as professional advice or therapy. If you are in need of mental health support, you are encouraged to connect with a licensed mental health professional to receive the support needed.Mental Health Resources: National Suicide Prevention Lifeline: 1-800-273-8255SAMHSA's National Helpline: 1-800-662-HELP (4357)Crisis Text Line: Text HOME to 741741 for free, 24/7 crisis counseling.Intro music by Coma-Media on ⁠⁠pixabay.com⁠

MENÚ DEL DÍA00:16 Bienvenida01:16 Pillada a Nerea04:05 El fin del universo está más cerca06:17 ¿Vida extraterrestre confirmada?08:14 Pelis que no pueden verse dobladas09:34 ¿Por qué el helio te cambia la voz?12:19 Los canales de difusión13:06 El anuncio de línea directa17:05 Las dos voces del Rubius18:59 El efecto mariposa20:05 Sin el pintor austriaco no habría manga24:13 No habría mamma mia sin naciolos26:48 La peli de Minecraft no existiría sin el Apollo XIII28:55 Sin esto no habría 50 sombras de Grey32:25 Ayala no habría salido en La Revuelta sin nosotros34:08 Oscar, el palomo cojo36:53 Los Whatsapps del Perro Sanxe39:28 REDDIT: Le prohibí la entrada a mi marido después de dar a luz48:26 Despedida

This is part one of a two-part recapBen is out for the week, so Ronnie invites the hysterical and on point Lara Schoenhals (@larzmari) for SUP (sexyuniquepod) to talk all things The Valley. This week, Mariposa enacts her revenge plan on Jason and Janet and Lala shows up to tell Jesse what a piece of crap he is. For those of you into violins, they play again this week for poor, poor Jax who sends in a video message telling us how much he loves his son before he wrecks his and his mothers finances. You can watch this recap on video, listen to our 3 part Road Trip bonus episodes, and participate in live episode threads at patreon.com/watchwhatcrappens. Tickets for our North American tour on sale at watchwhatcrappens.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This is part two of a two-part recapBen is out for the week, so Ronnie invites the hysterical and on point Lara Schoenhals (@larzmari) for SUP (sexyuniquepod) to talk all things The Valley. This week, Mariposa enacts her revenge plan on Jason and Janet and Lala shows up to tell Jesse what a piece of crap he is. For those of you into violins, they play again this week for poor, poor Jax who sends in a video message telling us how much he loves his son before he wrecks his and his mothers finances. You can watch this recap on video, listen to our 3 part Road Trip bonus episodes, and participate in live episode threads at patreon.com/watchwhatcrappens. Tickets for our North American tour on sale at watchwhatcrappens.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Antonio Vega, Efecto Mariposa, Pablo López, Galván Real, Maka, Vicente El Vizio, Bob Marley, Lola Indigo y más artistas . Un viaje diario a través de la buena música, disfruta y goza cada dia con Estación GNG, una dosis diaria de éxitos musicales del ayer y hoy. Que nada nos pare, disfruten con la música. Paz y música

Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Gilberto Lopes, a thoracic medical oncologist from the Sylvester Cancer Center. Together, they dived into the latest updates on anti-EGFR drugs used in non-small cell lung cancer (NSCLC) with EGFR mutations. In this informative discussion, they covered: •⁠  ⁠The evolution of EGFR inhibitors, including Afatinib, Osimertinib, Amivantamab, and Lazertinib. •⁠  ⁠Common side effects associated with these treatments, such as diarrhea, skin toxicity, and infusion-related reactions. •⁠  ⁠Strategies for managing these side effects to improve patient quality of life and treatment adherence. •⁠  ⁠Insights from recent studies, including the SKIPirr trial and the MARIPOSA study, highlighting the benefits of new combinations and treatment approaches. Youtube: https://youtu.be/v6fb6nx0YY4 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Join us as we explore how proactive management of side effects can maximize the effectiveness of these therapies and enhance patient outcomes. Don't forget to check out our other ToxCheck discussions, treatment algorithms, and conference highlights!

Gods above have gifted us glory because this week we're discussing season 3, episode 36 of Lucha Underground entitled "The Rise of the Ring Announcer". Come along as we chat about the episode, plus how-do-you-dos, the Batman / Scooby-Doo Mysteries, egging, episode 41 of Mostly Speakin' Sentai entitled, "Did You Say Cucked?", Ric Flair, jeans, Lucha mask culture, wigs, sauciness, non-verbal, Dante Fox praise, yellow lunch boxes, under utilizing Mariposa, crying on stage, Street Fighter 2, the Shaggy doubt, & more!Want to hear more from your favorite Marsh Land Media hosts? Hear exclusive shows, podcasts, and content by heading toPatreon.com/MLMpod!Buy some Shuffling the Deck / MLMpod MERCH, including our "Natty With Otters" shirt, over at redbubble.com/shop/msspod!Follow James @MarshLandMedia on Twitter, @MLMpod on Instagram, and listen to his music under "Marsh Land Monster" wherever music is found! Follow Sean on Twitter @SeanMarciniak and on Twitch @GooseVK! Join ourDiscord!Have fan mail, fan art, projects you want us to review, or whatever you want to send us? You can ship directly to us using "James McCollum, PO Box 180036, 2011 W Montrose Ave, Chicago, IL 60618"! Send us a voice mail to be played on the show at (224) 900-7644!Find out more about James' other podcasts "Mostly Speakin' Sentai", "Hit It & Crit It", and "This Movie's Gay" on our website,www.MLMPod.com!!! Plus, download all Marsh Land Monster albums there, too!

"What kind of saber are you rockin?"Mariposa and Archie bite off more than they can chew during a nighttime canyon crawl. Episode Artwork by @shaunmakesAudio Production by Astronomic AudioMusic by Duke Albert, John Julius, Mike Hammock, and Shubert Featuring:Shaun as The Game MarshalCristina as Mariposa Dela Cruz RosalesDan as Archie ElseworthJanette as Killdread SprainsShubert as Billy Bigtoes — Need More Bob in Your Life?  Check out our other (SFW!) podcast, Tales of Bob Apple Podcasts Spotify — Support the Show: Patreon Merch Store Contact Us: Discord TheHouseOfBob.org Twitter Instagram Facebook Email — Thank you so much to our current Patreon supporters! This podcast would not be possible without you. Michael Carlos G Shaka Jamal Ethan Edwards Dan Klip-Klop Elli The Pink Pastor Garbanzo D Chan Anette E Jordan Thomas Kuhlmann Connor McColloch Padraig Hegarty Brandon Knox Team EAMONN Pavel Lishin Christine Braille Tom Inns Elias Anderson Mark Boykin Jessica Colvin Scooter Emerson Josh Jordan Keith Haddad Tom Wesley Jessica

"What kind of saber are you rockin?"Mariposa and Archie bite off more than they can chew during a nighttime canyon crawl.Episode Artwork by @shaunmakesAudio Production by Astronomic AudioMusic by Duke Albert, John Julius, Mike Hammock, and ShubertFeaturing:Shaun as The Game MarshalCristina as Mariposa Dela Cruz RosalesDan as Archie ElseworthJanette as Killdread SprainsShubert as Billy Bigtoes—Need More Bob in Your Life? Check out our other (SFW!) podcast, Tales of BobApple PodcastsSpotify—Support the Show:PatreonMerch StoreContact Us:DiscordTheHouseOfBob.orgTwitterInstagramFacebookEmail—Thank you so much to our current Patreon supporters! This podcast would not be possible without you.MichaelCarlos GShaka JamalEthan EdwardsDan Klip-KlopElliThe Pink PastorGarbanzoD ChanAnette E JordanThomas KuhlmannConnor McCollochPadraig HegartyBrandon KnoxTeam EAMONNPavel LishinChristine BrailleTom InnsElias AndersonMark BoykinJessica ColvinScooter EmersonJosh JordanKeith HaddadTom WesleyJessica

la Mariposa y la Realidad

In March 2021, workers at the Mariposa Food Co-Op in West Philly formed a union with UFCW Local 1776. Today, they're working to build more power in order to make Mariposa into an even better place to work. Originally aired: February 13, 2023.Support the showwww.laborjawn.com

Conafor reporta 77 incendios activos en 17 estadosImpugnarán a "una veintena" de candidatos al Poder JudicialIsrael prometió represalias contra el régimen de IránMás información en nuestro Podcast

Una oruga que sueña con ser la mariposa mensajera de la primavera comienza su viaje con fe y valentía.Mi Instagram:⁠⁠https://instagram.com/cuentos_e_historias_infantiles⁠⁠Mi Facebook:⁠⁠https://www.facebook.com/CuentosHistoriasMexico⁠

The Mariposa Center for Safety, based out of Pueblo, does wonderful things to help people who are victims of domestic violence. Hear about the awesome event they've got coming up for Mother's Day and how you can help!Follow us for even more fun local radio content!https://www.facebook.com/x1039radio https://www.instagram.com/x1039radio

Recorded by Mariposa Fernández for Poem-a-Day, a series produced by the Academy of American Poets. Published on April 29, 2025. www.poets.org

Welcome back to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Joshua Sabari, a thoracic medical oncologist from NYU, to discuss the latest findings from the European Lung Cancer Conference (ELCC) 2025. We dived into several key studies that are shaping the future of lung cancer treatment, including: • KEYNOTE-799: Exploring the combination of concurrent chemotherapy and radiation with the PD-1 inhibitor pembrolizumab for unresectable non-small cell lung cancer (NSCLC). • LAURA: The impact of osimertinib in patients with EGFR mutations post-chemoradiation therapy. • MARIPOSA: The promising results of amivantamab and lisertinib in the metastatic setting for EGFR-mutated NSCLC. • KRYSTAL-7: Investigating the use of KRAS G12C inhibitors in frontline therapy. Join us as we discuss the implications of these studies, the importance of next-generation sequencing (NGS), and how to manage side effects associated with these new therapies. YouTube: https://youtu.be/akoXXAUEl_8 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology! #Oncology #LungCancer #ELCC2025 #EGFR #KRAS #CancerResearch #Podcast

Oncology here & nowIn this interview Dr. Biagio Ricciuti of Dana Farber Cancer Institute (USA) talks to Dr. Marcelo Corassa of beneficência Portuguesa de São Paulo (Brazil) as they discuss Treatments in EGFR mutant Non Small Cell Lung Cancer. The discussion centers around the results of FLAURA, MARIPOSA and FLAURA2, future directions and much more.Join Us

Hosted on Acast. See acast.com/privacy for more information.

WWF-México y la Comisión Nacional de Áreas Naturales Protegidas de México, en colaboración con las comunidades locales, realizaron un informe sobre la población de mariposas monarca migratorias en el país. Eduardo Rendón Salinas, director de Ecosistemas Terrestres WWF México, habló en Aristegui sobre las principales amenazas que enfrentan estas mariposas en el continente y puntualizó los logros alcanzados en la conservación de esta especie. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Apúntate para unirte al Club Agibílibus: ⁠⁠⁠https://borjaprofe.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠También recibirás un regalo CANÍBAL y más contenidos chulos cada semana.Gracias a Laura por venirse al podcast :) Puedes conocerla mejor en:⁠IG: @soy.lauraserranoNewsletter: https://subscribepage.io/W31LY5

In this intimate and candid episode, we sit down with Mariposa Coalson (@suchagreatsky), a transgender artist and comedian making waves in New York City's creative scene. Joined by her roommate Gabriel Gara Lonning, Mariposa takes on thought-provoking questions from the MTF Reddit community, offering honest insights and personal experiences. The conversation takes unexpected turns as Gabriel shares his own journey of exploring identity, including the surprising challenges of shopping for a changing body, and offers a critical perspective on conformity within the trans community. Raw, funny, and refreshingly honest, this episode dives deep into the realities of gender, identity, and finding authenticity in the big city.https://www.patreon.com/c/garalonningSupport the show

Tercer Milenio 360 Internacional - 10/03/25Fin de semana de terror en Siria. Al menos mil muertos en choques entre fuerzas leales al ex presidente Bashar Al Assad y fuerzas de seguridad oficiales. La liga Árabe condena la violencia.Se duplica la superficie de bosque ocupada por la mariposa monarca en México debido a las mejores condiciones climatológicas.La tarde del 3 de marzo del 2025, residentes de Miami, Florida, captan lo que parece ser un portal dimensional o magnético.Sao Paulo,  Brasil, se ha convertido en zona de intensa actividad OVNI. La noche del 3 de marzo, un residente registra con su teléfono celular un objeto brillante con base cuadrangular que se desplazaba lentamente y en linealidad recta.  

Primer transplante de corazón este 2025 se realizó en el IMSS Aumentó al 99% la presencia de la mariposa monarca en México  EU debe enfrentar el problema del fentanilo:China  Más información en nuestro podcast 

We're joined by Bridget Fithian, Executive Director of the Sierra Foothill Conservancy and a leader in land conservation across the Central Sierra. Born and raised in Mariposa, Bridget's deep connection to open spaces has shaped her career in conservation, where she has helped protect over 30,000 acres of land through innovative partnerships and creative solutions.  Under her leadership, the Sierra Foothill Conservancy has expanded public access to nature, preserved critical landscapes, and played a key role in conservation planning, fire resilience, and environmental stewardship. Bridget also serves as Board Chair of the California Council of Land Trusts and holds leadership roles with the Sierra Cascade Land Trust Council and the California Conservation Action Fund.  In this episode, we'll explore how land trusts shape conservation, the role of environmental planning, and what it takes to protect and restore California's landscapes for future generations.  

Aprovecha la promoción exclusiva de NordVPN y Leyendas Legendarias y obtén 4 meses gratis: https://nordvpn.com/legendarias Notas Macabrosas - Muere un joven de 14 años por inyectarse 'jugo de mariposa' - Una prueba de ADN confirma que las lágrimas de la Virgen de Trevignano eran de una vidente - Presunto artefacto explosivo resulta ser un envase de perfume - Escapando de la “granja de huevos humanos”: tres mujeres escapan de una impactante red de tráfico de personas - Mujer se divorcia porque su esposo abucheó a Taylor Swift en Super Bowl - Atleta de 17 años murió mientras levantaba una barra con 270 kg  - 157 delfines fueron hallados varados en una playa de Tasmania  - California avanza hacia el reconocimiento oficial de Bigfoot  - Rescatan a hombre encerrado en baño de Elektra  - Hombre es detenido en aeropuerto con 19 cápsulas de cocaína en una peluca  - Un hombre mata a su esposa después de que un medidor paranormal le provocara temores de que ella se lo comería Redditeando - Lolo nos trae un hilo de reddit con respuestas a la pregunta: ¿Cuál es tu “rasgo de asesino en serie” que (hipotéticamente) haría que todos dijeran: “Deberíamos haberlo sabido”? También puedes escucharnos en Youtube, Spotify, Apple Podcasts, Amazon Music o tu app de podcasts favorita. Apóyanos en Patreon: https://www.patreon.com/leyendaspodcast​ Apóyanos en YouTube: https://www.youtube.com/c/leyendaslegendarias/join Síguenos: https://instagram.com/leyendaspodcast​ https://twitter.com/leyendaspodcast​ https://facebook.com/leyendaspodcast​ #Podcast​ #LeyendasLegendarias​ #HistoriasDelMasAca Learn more about your ad choices. Visit megaphone.fm/adchoices

Aprovecha la promoción exclusiva de NordVPN y Leyendas Legendarias y obtén 4 meses gratis: https://nordvpn.com/legendarias Notas Macabrosas - Muere un joven de 14 años por inyectarse 'jugo de mariposa' - Una prueba de ADN confirma que las lágrimas de la Virgen de Trevignano eran de una vidente - Presunto artefacto explosivo resulta ser un envase de perfume - Escapando de la “granja de huevos humanos”: tres mujeres escapan de una impactante red de tráfico de personas - Mujer se divorcia porque su esposo abucheó a Taylor Swift en Super Bowl - Atleta de 17 años murió mientras levantaba una barra con 270 kg  - 157 delfines fueron hallados varados en una playa de Tasmania  - California avanza hacia el reconocimiento oficial de Bigfoot  - Rescatan a hombre encerrado en baño de Elektra  - Hombre es detenido en aeropuerto con 19 cápsulas de cocaína en una peluca  - Un hombre mata a su esposa después de que un medidor paranormal le provocara temores de que ella se lo comería Redditeando - Lolo nos trae un hilo de reddit con respuestas a la pregunta: ¿Cuál es tu “rasgo de asesino en serie” que (hipotéticamente) haría que todos dijeran: “Deberíamos haberlo sabido”? También puedes escucharnos en Youtube, Spotify, Apple Podcasts, Amazon Music o tu app de podcasts favorita. Apóyanos en Patreon: https://www.patreon.com/leyendaspodcast​ Apóyanos en YouTube: https://www.youtube.com/c/leyendaslegendarias/join Síguenos: https://instagram.com/leyendaspodcast​ https://twitter.com/leyendaspodcast​ https://facebook.com/leyendaspodcast​ #Podcast​ #LeyendasLegendarias​ #HistoriasDelMasAca Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Jyoti Patel is back on the podcast to discuss the updates to the living guideline on therapy for stage IV NSCLC with driver alterations. She shares updated recommendations in the first- and second-line settings for patients with stage IV NSCLC and classical EGFR mutations, and the impact of these updates for clinicians and patients. We also look to the future to discuss ongoing developments in the field. Read the full living guideline update “Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3” at www.asco.org/living-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/living-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-24-02785     Brittany Harvey: Welcome to the ASCO Guidelines Podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges and advances in oncology. You can find all the shows including this one at asco.org/podcasts.   My name is Brittany Harvey and today I'm interviewing Dr. Jyoti Patel from Northwestern University, co-chair on “Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3.” It's great to have you back on the show today, Dr. Patel. Dr. Jyoti Patel: Thanks so much. Happy to be here. Brittany Harvey: And then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Patel, who has joined us here today, are available online with the publication of the guideline and in the Journal of Clinical Oncology, which is linked in the show notes. So then, to dive into the content of this update, Dr. Patel, this clinical practice guideline for systemic therapy for patients with stage IV non small cell lung cancer with driver alterations is living, meaning that it's continuously reviewed and updated. So what data prompted this latest change to the recommendations? Dr. Jyoti Patel: Thanks so much. So it's really been an exciting time in the treatment of EGFR lung cancer, particularly this past year has required us to rethink approaches to front- and second-line therapy. In this particular update, we examined what patients in the front-line setting may be offered by their clinicians. And so we're talking about the population of classical EGFR mutations, so exon 19 and exon 21 L858R substitution. And so certainly for this population, osimertinib has a high level of evidence and should be offered to all patients at the time of diagnosis when they present with advanced disease. Our last update included a recommendation that patients could also get platinum doublet chemotherapy with osimertinib or osimertinib alone. This current recommendation also introduces another alternative therapy and that's the combination of amivantamab plus lazertinib. And so now, clinicians are faced with three really good options for their patients with EGFR exon19 deletion or L858R. Brittany Harvey: It's great to hear that there's this advance in the space, particularly for patients with these classical EGFR mutations that you mentioned. So what should clinicians know as they implement these new first-line recommendations? Dr. Jyoti Patel:  I think it's become more complex than ever. Certainly, we know again that patients should get osimertinib in the frontline setting. But we've been kind of stuck at progression-free survival that's between a year and a half and two years. And so we've really been looking at opportunities to intensify therapy. So one could certainly be with chemotherapy or switching over to amivantamab, the bispecific antibody that targets EGFR and MET plus lazertinib, an oral TKI that's very similar in structure to osimertinib. And when you're talking to a patient, it's really a conversation about balancing efficacy with toxicity. Unfortunately, as we know, there aren't that many free lunches. And so if we think about what a patient is hoping for in their therapy and how we can further personalize treatment options, really is important to look at some of the analyses for this study. So in the study of amivantamab plus lazertinib, we know that there were increased toxicities with a combination of both therapies. In fact, up to 75% of patients had over grade 3 toxicities, versus about 43% of patients with osimertinib monotherapy. And we know if we look back at FLAURA2, almost two thirds of patients with osimertinib and chemotherapy had grade 3 toxicities, compared to 27% of patients with osimertinib alone. So we certainly see an increase in toxicities. Then we have to ask ourselves, are those paper toxicities or ones that really impact patients? And we know that amivantamab, for example, causes significant cutaneous toxicities. With both of these therapies, whether it's chemotherapy or adding amivantamab, there's the burden of infusional visits and increased time in the doctor's office. Certainly with chemotherapy, there can be an increased incidence of myelosuppression. And so when we're thinking about advising our patients, certainly we need to talk about the toxicities. But one thing that we've been able to do is to look at the patients that were included in this trial. And what we really find is that in higher risk cohorts, particularly those that we know historically have done less well with standard osimertinib, so patients, for example, with CNS metastasis, for those patients with co-mutations, it may be that that additive benefit is significant. And so one example I think would be from the MARIPOSA study, again, the study of amivantamab and lazertinib versus chemotherapy. What we can say is that patients who had co-mutations, so patients with EGFR mutations as well as TP53, lazertinib and amivantamab led to a hazard ratio of 0.65 compared to osimertinib alone. So that was 18.2 months versus 12.9 months. And so this may be really important to patients. And we also see conversely that patients with wild type TP53, so those patients who didn't have the mutation, probably had equivalent survival regardless of therapy. So certainly, we need to prospectively study some of these high-risk cohorts. We've only seen progression-free survival in these studies. And so at this juncture, we can advise our patients about toxicity, the improvements in certain categories of progression-free survival, but we really still don't know how this pans out in overall survival. In many of these studies, all patients do not necessarily cross over to the study arm and so they may have lost the benefit of subsequent therapy. Brittany Harvey: Absolutely. It's very important to talk about that balance of benefits and risks and particularly those toxicities that you discussed. So I appreciate reviewing that recommendation and the considerations for clinicians for first-line therapy. This update also included a second-line treatment update. What is that update for patients with EGFR alterations? Dr. Jyoti Patel: So this is where it gets super tricky because we have a frontline option with amivantamab and now we've had an update in the second line option. So what we said is that for patients who have progressed on an EGFR TKI, and in the United States, certainly that's predominantly osimertinib, or those in other parts of the world that may have gotten an earlier generation TKI, but do not have evidence of T790M or other targetable mutations, we can offer patients chemotherapy with or without amivantamab. And so certainly we have seen that this again leads to improved survival. There have also been a number of studies looking at incorporation of PD-L1 and anti-VEGF therapies. And what we can say, I think pretty clearly is that multiple phase 3 trials have really shown no benefit of the addition of PD-1 to platinum chemotherapy. But there are some emerging bispecific antibodies that may target PD-1 as well as VEGF, or combinations of antibodies that target both of those pathways that may improve outcome. At this juncture, I think we feel that the evidence surrounding chemotherapy plus amivantamab is strongest, but there is certainly work in this space that will be of interest. Now, what happens if your patient received amivantamab and lazertinib in the frontline setting and then has progression? And so we're trying to understand resistance mechanisms and opportunities for treatment. What the panel decided to recommend, based on the available evidence, was that certainly those patients should get platinum-based chemotherapy, but there may also be a role for antivascular endothelial growth factor targeting therapy such as bevacizumab in patients in whom it would be safe. Brittany Harvey: Great. I appreciate you detailing those recommendations when it gets complicated in the second-line setting. So what should clinicians know as they implement these second-line recommendations too? Dr. Jyoti Patel: So certainly the frontline setting matters significantly. So if a patient gets osimertinib in the frontline setting, we generally suggest that patients undergo repeat testing to see if they have another targetable mutation. If they don't, then I think preferred therapy would be chemotherapy with or without amivantamab. And amivantamab leads to a significant improvement in progression-free survival and response rate at the cost of increased risk of toxicity. For patients who get FLAURA2 in the frontline setting, chemotherapy plus osimertinib, it's a little bit of an unclear space. Those patients most likely would get docetaxel with or without ramucirumab. But there are other agents that we hope to have available to our patients in the near future. For patients who receive amivantamab and osimertinib, we recommend that those patients get chemotherapy probably with anti-VEGF as demonstrated by multiple trials that have shown the improved progression-free survival with introduction of an anti-VEGF agent. And we've seen evidence of amivantamab in the third line setting, so it is likely that this question about sequencing really takes center stage in our next set of trials. When you're talking to a patient, I think again, it's absolutely important to discuss: What are their goals? How symptomatic or how fast is their progression? Are there ways in which patients may benefit from spot treatment oligoprogression such as radiation? When is the right time for introduction of amivantamab and when do we think patients need chemotherapy? Is it up front or predominantly in the second-line setting? Brittany Harvey: Definitely. And then you've just touched on the goals of treatment for individual patients. So in your view, what does this update mean for patients with stage IV non-small cell lung cancer and an EGFR alteration? Dr. Jyoti Patel: For patients, this is a time in which shared decision making really needs to take center stage. So our best patients are those patients that are best informed not only about their disease but also have a good understanding about what is important to them and their families in terms of care. And so bringing that shared understanding to the table again helps us think about this particular cancer as more of a journey rather than just a one off treatment. Therapy will hopefully be prolonged, and so it's absolutely important that we address toxicities, make therapies more tolerable, again, with the shared goal of living long and living well. Brittany Harvey: Absolutely. Those are key points to making sure that patients are living both longer and have a good quality of life during that time as well. So then, before you mentioned the possibility of future sequencing trials and other ongoing developments. What additional studies or future directions is the panel examining for future updates to this living guideline? Dr. Jyoti Patel: So certainly we're thinking about trials that look at, for example, cfDNA clearance. So are there patients that do well and can we detect that early on without having to intensify therapy on day 1 so it may be that we add chemotherapy a little bit later. I think really exciting are some of the new bispecific. The HARMONi-A trial was a trial in China of a novel bispecific, ivonescimab. And this drug targets both PD-1 and VEGF and it was combined with chemotherapy. And this trial found almost a doubling of progression-free survival with this drug in combination chemotherapy in an EGFR patient population. That study is being planned and being run in the United States to see if we have similar outcomes with a more diverse population. So certainly that's exciting. There are a number of antibody drug conjugates that are being studied in the post-chemotherapy setting as well. And I think we'll likely soon see a better understanding of what co-mutations and burden of disease really mean when we're thinking about assigning treatment. So which patients, again, need intensification of therapy and which patients may do really well on just an oral agent that they're taking at home with more tolerable toxicity than dual treatment. Brittany Harvey: Yes, we'll look forward to continued developments in these fields and seeing some of those studies come to fruition. So with that, I want to thank you for your work to rapidly and continuously update this guideline, and thank you for your time today, Dr. Patel. Dr. Jyoti Patel: Thanks so much, Brittany. It's really an exciting time for lung cancer and we hope that these updates really help physicians decide the best treatments for their patients. Again, it's a rapidly evolving landscape which is fantastic, but it does become more cumbersome to stay ahead of the literature. Brittany Harvey: Definitely. And so we appreciate your time and the panel's time spent reviewing this literature and providing this much needed information to clinicians everywhere. So finally, thank you to all of our listeners for tuning into the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/living-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app available in the  Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Biochemical and forensic experts from the Science and Technology Directorate (S&T) and Pacific Northwest National Laboratory (PNNL) visited one of the nation's busiest (and loudest) ports of entry in Mariposa, Arizona. With this as our backdrop, listen as the group discusses research and development of a novel fentanyl detector designed to improve screening for illicit drugs. S&T's Dan Conway leads a conversation with Dr. Andrea Wiggins of S&T's Chemical Biological Detection and Defense Program; Travis Brown, S&T Program Manager for Forensics and Criminal Investigation; Dr. Laura Parker, S&T Senior Advisor on Sensors and Detection; and PNNL Senior Research Chemist Dr. Robert Ewing about how this new technology was demonstrated and could soon be used and overall challenges with combating the flow of fentanyl.

We meet legendary artist Peter Berlin from his home in San Francisco. Peter Berlin (born Armin Hagen Freiherr von Hoyningen-Huene) is a photographer, artist, filmmaker, clothing designer, model, and gay icon. Berlin started taking self-portraits of himself in the 1970s. By modifying his clothes, choosing various props and settings, and sometimes using double-exposure to create a second image, Berlin would photograph himself in ways that create a hyper-sexualized, overtly masculine image.We explore Mariposa Gallery's inaugural Los Angeles exhibition featuring the groundbreaking photography, art, and personal artifacts of Peter Berlin, an artist who transformed queer self-representation and male eroticism in the 1970s and beyond. The exhibition set to open at 526 N. Western Avenue—in the heart of the Melrose Hill gallery district— is curated by actor and host of Talk Art, Russell Tovey, and will showcase Berlin's iconic self-portraits, unique painted photographs, and items from his personal archive including his own clothing designed by Berlin during his years as a self-styled gay icon. This is the first ever exhibition of Berlin's work in Los Angeles.The exhibition offers visitors a rare view into the life and work of an artist whose influence on LGBTQ+ aesthetics endures. Berlin, born Armin Hagen Freiherr von Hoyningen Huene in 1942, gained notoriety for his daring and meticulously crafted self-portraits, often taken in public spaces across Berlin, Paris, New York, and San Francisco. These images capture Berlin in his skin-tight costumes and signature pageboy haircut, boldly challenging the boundaries of masculinity and public identity.Berlin's focus on “cruising as career” drew him to create self-portraits that explored male sexuality and queer expression, which appeared on the covers of numerous gay publications, cementing his image as an international gay sex symbol. The exhibition will also feature selections from Berlin's '70s and '80s media presence, capturing the evolution of gay aesthetics in this era."Peter Berlin, the fearless and enigmatic, otherworldly icon of 1970s cruise culture, created work that resonates around the world—sparkling, searing, and blazing with vitality. His images burn with eternal desire, offering us the ultimate permission to stare. It's a privilege to share his groundbreaking art with new and familiar audiences alike. Peter Berlin remains a profoundly significant yet often overlooked figure in the history of art." - Russell ToveyBerlin's influence extended to film, including Nights in Black Leather (1973) and That Boy (1974), both now cult classics. A recent 2019 monograph on his work, Icon, Artist, Photosexual, highlights his impact, featuring insights from Michael Bullock, Evan Moffitt, and Ted Stansfield, each celebrating Berlin's singular contribution to queer art and culture. Mariposa Gallery invites the public to step into Berlin's world and experience the legacy of an artist who, through bold self-exploration and defiant artistry, redefined eroticism and individuality in the queer community.Materials on loan from the Peter Berlin Collection courtesy of Armin Hagen von Hoyningen-Huene and with guidance from Gerard Koskovich, the historian and dealer offering the collection for institutional acquisition. For more information, visit www.abaa.org/booksellers/details/gerard-koskovich-queer-antiquarian-books.Follow @PeterBerlinSF and @Mariposa.DriveVisit: https://www.mariposa.gallery/berlin Hosted on Acast. See acast.com/privacy for more information.

Excellence abounds at 1850 Brewing in Mariposa, California. And then Bob had to bring in some other mess just so we could all appreciate the excellence.

Screw cousins, these wrestlers are snoggin' siblings because this week we're discussing season 3, episode 23 of Lucha Underground entitled "Family First". Come along as we chat about the episode, plus sphincters, a new Fenix, Hellboy, MST3k, "Big Momma's House 2", thighs / heads, "The Grease", urine, "Gauntlet Legends", Snopes, pewb mounds, "Scary Movie 2", esophagus pronunciations, DX Chops, DQing wrestlers not in the ring, live commentary, dropkicks, mist, & more!Want to hear more from your favorite Marsh Land Media hosts? Hear exclusive shows, podcasts, and content by heading toPatreon.com/MLMpod!Buy some Shuffling the Deck / MLMpod MERCH, including our "Natty With Otters" shirt, over atredbubble.com/shop/msspod!Follow James @MarshLandMedia on Twitter, @MLMpod on Instagram, and listen to his music under "Marsh Land Monster" wherever music is found! Follow Sean on Twitter @SeanMarciniak and on Twitch @GooseVK! Join ourDiscord!Have fan mail, fan art, projects you want us to review, or whatever you want to send us? You can ship directly to us using "James McCollum, PO Box 180036, 2011 W Montrose Ave, Chicago, IL 60618"! Send us a voice mail to be played on the show at (224) 900-7644!Find out more about James' other podcasts "Mostly Speakin' Sentai", "Hit It & Crit It", and "This Movie's Gay" on our website,www.MLMPod.com!!! Plus, download all Marsh Land Monster albums there, too!

Científicos registran uno de los vuelos más largos que ha hecho una mariposa: 3,000 kilómetros de distancia. Esucha esta y otras noticias positivas.

¡Sean ustedes bienvenidas al episodio 93 de esta temporada! El día de hoy hablaremos de la obra: “Los Miserables” de Victor Hugo. ¿Qué nos enseña esta historia sobre la ley y la misericordia? Esta historia ha sido llevada a teatros en Broadway y a la pantalla grande en varias ocasiones. ¡Muchas gracias por ser parte de esta comunidad! No lo olvides. ¡Estamos juntas en esto! Todos los derechos reservados. Copyright 2025 © Estíbaliz Delgado Amaya

El Sueño de la Mariposa

CORREOS CON LOS QUE SE DIO LENGUA: